Together, our findings from these animal experiments strongly suggest that pharmacological inhibition of REV-ERBα is effective in suppressing tumor LP programs and that REV-ERBα is an attractive therapeutic target for ARSI-resistant tumors. This evidence concerns the gene NR1D1 and neoplasm.